Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Keeping Things Moving in the Treatment of Chronic Idiopathic Constipation: Exploring the Evidence and Guidelines Through Case Studies

Premiere Date: Tuesday, October 26, 2021

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Wednesday, October 26, 2022
Note: Credit Is No Longer Available

Faculty

William D. Chey, MD, AGAF, FACG, FACP (Moderator) Timothy T. Nostrant Collegiate Professor of Gastroenterology Professor of Nutrition Sciences Chief, Division of Gastroenterology & Hepatology Departments of Internal Medicine and Nutritional Sciences Michigan Medicine University of Michigan Ann Arbor, MI

Michael Camilleri, MD  Atherton and Winifred Bean Professor of Medicine, Pharmacology, and Physiology Mayo Clinic Rochester, MN

Lucinda A. Harris, MS, MD, FACG, AGAF, FACP  Associate Professor of Medicine Consultant, Division of Gastroenterology and Hepatology Mayo Clinic - Alix School of Medicine Scottsdale, AZ

Statement of Need

Chronic idiopathic constipation (CIC) is a common gastrointestinal disorder that affects 35 million adults in the United States. However, despite its prevalence, it is often underdiagnosed, undertreated, and mismanaged. This has resulted in substantial functional, psychosocial, and economic consequences; therefore, it is imperative that clinicians are informed on how best to diagnose and provide comprehensive care for patients with CIC.

This CMEO webcast will focus on how to differentiate CIC from constipation-predominant irritable bowel syndrome (IBS-C) for early and accurate diagnosis and will provide data on current therapies used in the management of CIC in order for clinicians to better understand how to develop comprehensive treatment strategies.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Accurately diagnose CIC, differentiating it from IBS-C.
• Evaluate the characteristics of therapies used in the management of CIC.
• Develop a comprehensive treatment strategy for patients with CIC, constructed from evidence and clinical guidelines.

Financial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Gastroenterologists, primary care physicians, PAs, nurse practitioners, nurses, pharmacists

Credit Information

ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Chey reports that he receives research support from Biomerica, Inc.; Commonwealth Diagnostics International, Inc.; U.S. Food and Drug Administration (FDA); National Institutes of Health (NIH); QOL Medical; and Salix Pharmaceuticals. He is a consultant for AbbVie Inc; Alnylam Pharmaceuticals Inc.; Arena Pharmaceuticals, Inc.; Biomerica, Inc.; Cosmo Pharmaceuticals; Gemelli Biotech; IM Health; Ironwood Pharmaceuticals, Inc.; Nestle; Phathom Pharmaceuticals; Progenity, Inc.; QOL Medical; RedHill Biopharma Inc.; Salix Pharmaceuticals/Valeant Pharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.; Urovant Sciences, Inc.; and Vibrant Pharma Inc. He is a stock shareholder (directly purchased), options: GI OnDEMAND and ModifyHealth, LLC.

Dr. Camilleri reports that he receives grants from Allergan; Arena Pharmaceuticals; ILSI North America; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals. He is a consultant for AEON Biopharm; Alfasigma USA, Inc.; Allakos Inc.; Allergan; Arena Pharmaceuticals U.S.A, Inc.; AstraZeneca; BioKier, Inc.; Coloplast Corp; EA Pharma Co., Ltd.; ElobixAB; GlaxoSmithKline; Ironwood; Kallyope; Metornic; Novome Biotechnologies, Inc.; Pfizer Inc.; Protagonist Therapeutics, Inc.; QED Therapeutics, Inc.; Rose Pharma; Salix Pharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.; and Virios Therapeutics. He receives other financial or material support as an option to receive stock for consulting with Bilayer Therapeutics; Dignify Therapeutics; Enterin Inc.; and Thelium Therapeutics.

Dr. Harris reports she is a consultant for AbbVie (formerly Allergan); Alnylam Pharmaceuticals, Inc.; Gemelli Biotech; GI Health Foundation; Ironwood Pharmaceuticals, Inc.; Rome Foundation; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc. (Formally Shire). She reports that she receives research support from Allakos.

Jeffrey Helfand DO, (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh, (peer reviewer) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).